8144
document
Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus -- a double blind randomized study . OBJECTIVE Parameters of oxidative stress were quantitated in 50 patients with type 2 diabetes mellitus in uncontrolled state and after control using oral glibenclamide or gliclazide . The estimates were further compared between the two groups irrespective of drug used to evaluate the difference , if any . METHODS The study was a double blind , uncontrolled , noncrossover and randomized trial . Fifty patients of uncontrolled type 2 diabetes were divided in to two groups . Group I ( 25 patients ) received capsule A ( glibenclamide ) while Group II ( 25 patients ) received capsule B ( gliclazide ) . The parameters studied were Superoxide dismutase ( SOD ) , malonyl-dialdehyde ( MDA ) and reduced glutathione ( GSH ) . They were done at ( a ) uncontrolled stage ( FBS -- 165 +/- 16.7 mg/dl , PP -- 240 +/- 30.1 mg/dl and HbA1 -- 10.5 +/- 0.9 % in group I and FBS -- 150 +/- 15.8 mg/dl , PP -- 246 +/- 29.1 mg/dl HbA1 10.6 +/- 0.8 % in group II ) and during controlled stage at 12 weeks ( FBS -- 120 +/- 18.5 mg/dl , PP -- 180 +/- 19.1 mg/dl and HbA1 -- 8.4 +/- 0.29 % in group I and FBS -- 118 +/- 17.6 mg/dl , PP -- 176 +/- 20.1 mg/dl and HbA1 -- 8.5 +/- 0.39 % in group II patients ) . RESULTS The significantly raised levels of MDA and SOD , and decreased levels of reduced glutathione ( GSH ) during uncontrolled stage of diabetes indicated free radical stress induced lipid peroxidation . The significant fall of MDA and SOD and increased levels of GSH in blood in both groups after control revealed beneficial effects of glycemic control on oxidative stress . The levels were not normalized and stayed higher than those in controls . On intergroup comparison ; the control of diabetes with gliclazide ( group II ) showed improvement in oxidative stress ( MDA , GSH ) better ( p < 0.001 ) than glibenclamide ( group I ) . CONCLUSION Oxidative stress in uncontrolled diabetes is decreased with glycemic control . The control of diabetes with gliclazide reduced oxidative stress more than glibenclamide , indicating higher antioxidant properties of gliclazide . Normalization of oxidative stress was not achieved . Further studies are required to see long-term effect of drug therapy in combating oxidative stress after achieving acceptable control of diabetes .
8145
Intervention_Pharmacological
Glibenclamide
8146
Intervention_Pharmacological
gliclazide
8147
Intervention_Pharmacological
glibenclamide
8148
Intervention_Pharmacological
gliclazide
8149
Intervention_Pharmacological
glibenclamide
8150
Intervention_Pharmacological
gliclazide
8151
Intervention_Pharmacological
gliclazide
8152
Intervention_Pharmacological
glibenclamide
8153
Intervention_Pharmacological
gliclazide
8154
Intervention_Pharmacological
glibenclamide
8155
Outcome_Physical
oxidative stress
8156
Outcome_Physical
oxidative stress
8157
Outcome_Physical
Superoxide dismutase ( SOD )
8158
Outcome_Physical
malonyl-dialdehyde ( MDA )
8159
Outcome_Physical
reduced glutathione ( GSH )
8160
Outcome_Physical
levels of MDA and SOD
8161
Outcome_Physical
levels of reduced glutathione ( GSH )
8162
Outcome_Physical
fall of MDA and SOD
8163
Outcome_Physical
increased levels of GSH in blood
8164
Outcome_Physical
oxidative stress .
8165
Outcome_Physical
oxidative stress ( MDA , GSH )
8166
Outcome_Physical
Oxidative stress
8167
Outcome_Physical
oxidative stress
8168
Outcome_Physical
oxidative stress
8169
Outcome_Physical
oxidative stress
8170
Participant_Condition
noninsulin dependent diabetes mellitus
8171
Participant_Condition
type 2 diabetes mellitus in uncontrolled state
8172
Participant_Condition
uncontrolled type 2 diabetes